Back to Search
HUBERT LYERLY, PH.D.
PH.D.
Clinical Psychologist
NPI: 1972633246Individual
Specialties, Licenses & Credentials
Clinical PsychologistPrimary
Psychologist — Clinical
Code: 103TC0700X
1754(NC)
Research & Publications (20)
Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.
PMID 19229288·Cancer Gene Ther·2009
7-preclinical
MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition.
PMID 19603033·Br J Cancer·2009
8-other
Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology.
PMID 19394793·J Pain Symptom Manage·2009
3-trial
Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.
PMID 19351755·Clin Cancer Res·2009
7-preclinical
Translational Research Working Group developmental pathway for immune response modifiers.
PMID 18794077·Clin Cancer Res·2008
8-other
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.
PMID 18193223·Cancer Immunol Immunother·2008
8-other
Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data.
PMID 18761678·Health Serv Res·2008
8-other
Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.
PMID 18202008·Mol Cancer Ther·2008
8-other
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides.
PMID 18366814·BMC Immunol·2008
8-other
Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease.
PMID 18418774·Cytotherapy·2008
8-other
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.
PMID 18519811·Blood·2008
3-trial
CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.
PMID 17696823·Expert Opin Biol Ther·2007
6-review
Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.
PMID 17822557·J Transl Med·2007
3-trial
Investigation of HIFU-induced anti-tumor immunity in a murine tumor model.
PMID 17625013·J Transl Med·2007
7-preclinical
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.
PMID 17373897·Expert Opin Biol Ther·2007
6-review
Current immunotherapeutic strategies in colon cancer.
PMID 18022550·Surg Oncol Clin N Am·2007
6-review
Recent clinical progress in virus-based therapies for cancer.
PMID 17049011·Expert Opin Biol Ther·2006
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 800 EASTOWNE DR, SUITE 200
CHAPEL HILL, NC 27514 - Phone
- (919) 490-5503
Quick Facts
- NPI
- 1972633246
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile